- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04081220
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2
An Investigator Initiated Phase 2 Trial of the LSD1 Inhibitor IMG-7289 in Essential Thrombocythemia (CTMS# 19-0078)
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Patricia Manea, BSN
- Phone Number: 210-450-1821
- Email: maneap@uthscsa.edu
Study Contact Backup
- Name: Epp Goodwin
- Phone Number: 210-450-5798
- Email: goodwine@uthscsa.edu
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Recruiting
- Mays Cancer Center
-
Contact:
- Epp Goodwin
- Email: goodwine@uthscsa.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years.
- Diagnosis of Essential Thrombocythemia per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms (Arber et al., 2016).
3. Patients who are intolerant or resistant to hydroxyurea per ELN (European Leukemia Net) criteria, or in the Investigator's judgment are not candidates for available approved therapy. The ELN definitions of resistance/intolerance to HU (hydroxyurea) requires the fulfillment of at least one of the following criteria:
- Platelet count greater than 600 × 109/L after 3 months of at least 2 g/day of HU (2.5 g/day in patients with a body weight over 80 kg);
- Platelet count greater than 400 × 109/L and leukocytes less than 2.5 × 109/L or hemoglobin (Hb) less than 100 g/L at any dose of HU;
- Presence of leg ulcers or other unacceptable mucocutaneous manifestations at any dose of HU;
- HU-related fever.
- Requires treatment in order to lower platelet counts based on the Clinically Relevant IPSET (International Prognostic Score for Thrombosis in Essential Thrombocythemia) -Thrombosis Guidelines.
- Platelet count >450 x 109/L pre-dose Day 1.
- Peripheral blast count <10% pre-dose Day 1.
- ANC (absolute neutrophil count) ≥0.5 x 109/L pre-dose Day 1.
- Fibrosis Score ≤ grade 2, as per a slightly modified version (Arber et al., 2016) of the European Consensus Criteria for Grading Myelofibrosis, (Thiele et al., 2005).
- Life expectancy > 36 weeks.
- Able to swallow capsules.
- Amenable to spleen size determination, bone marrow evaluations, and peripheral blood sampling during the study.
- Must have discontinued ET therapy at least 2 weeks (4 weeks for interferon) prior to study drug initiation.
- Agrees to use an approved method of contraception from Screening until 28 days after last administration of the study drug. Acceptable methods of birth control include: birth control pills, depo-progesterone injections, a vaginal hormonal contraceptive ring, a barrier contraceptive such as a condom with spermicide cream or gel, diaphragms or cervical cap with spermicide cream or gel, or an intrauterine device (IUD).
- If male, agrees not to donate sperm or father a child for at least one month after the last dose of the study medication.
Exclusion Criteria:
- Greater than 3 separate transfusion episodes over the last 6 months and/or any transfusion over the last 4 weeks.
- Eastern Cooperative Oncology Group (ECOG) questionnaire score of 3 or greater.
- Currently pregnant or planning on being pregnant in the following 6 months or currently breastfeeding.
- Currently residing outside the United States.
- History of splenectomy.
- Unresolved treatment related toxicities from prior therapies (unless resolved to ≤ Grade 1).
- Uncontrolled active infection.
- Known positive for HIV or infectious hepatitis, type A, B or C.
- Current use of monoamine oxidase A and B inhibitors (MAOIs).
Evidence at the time of screening of increased risk of bleeding, including any of the following:
- Activated partial thromboplastin time (aPTT) > 1.3 x the upper limit of normal
- International normalized ratio (INR) >1.3 x the local upper limit of normal
- Known Acquired Von Willebrand's disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IMG-7289
|
Single starting dose with individualized dose titrations throughout
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of patients who achieve complete hematologic remission
Time Frame: 24 weeks using ELN (European Leukemia Net) criteria for ET (essential thrombocythemia)
|
24 weeks using ELN (European Leukemia Net) criteria for ET (essential thrombocythemia)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Zohra Nooruddin, MD, Mays Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTMS# 19-0078
- HSC20190791H (Other Identifier: UT Health Science Center San Antonio IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombocythemia, Essential
-
ShireCompletedEssential Thrombocythemia (ET)Japan
-
ShireCompletedEssential Thrombocythemia (ET)United Kingdom, Italy, Czechia, France, Germany, Greece, Spain, Switzerland
-
ShireCompletedEssential Thrombocythemia (ET)Italy
-
ShireCompletedEssential Thrombocythemia (ET)Japan
-
ShireCompletedEssential ThrombocythaemiaSweden, United Kingdom, Spain
-
AOP Orphan Pharmaceuticals AGCompletedEssential ThrombocythaemiaPoland, Slovakia, Bulgaria, Russian Federation, Romania, Croatia, Lithuania, Austria, Ukraine
-
AOP Orphan Pharmaceuticals AGCompletedEssential ThrombocythaemiaAustria, Czech Republic, France, Germany, Hungary, Italy, Lithuania, Poland, Singapore, Slovenia
-
ShireCompletedThrombocythemia, HemorrhagicBulgaria, France, Hungary, Poland, Portugal, Serbia
-
Institute of Hematology & Blood Diseases Hospital...RecruitingEssential ThrombocytopeniaChina
Clinical Trials on IMG-7289
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingPolycythemia Vera | Essential ThrombocythemiaUnited States
-
Merck Sharp & Dohme LLCNot yet recruitingPrimary Myelofibrosis | Polycythemia Vera | Thrombocythemia, Essential | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis
-
The University of Hong KongImago BioSciences,Inc.Recruiting
-
Imago BioSciences, Inc., a subsidiary of Merck...CompletedMyelofibrosis | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (PPV-MF) | Post-essential Thrombocythemia Myelofibrosis (PET-MF)Germany, United States, Australia, Italy, United Kingdom
-
Imago BioSciences, Inc., a subsidiary of Merck...Active, not recruitingPolycythemia VeraUnited States, Australia, United Kingdom
-
Imago BioSciences, Inc., a subsidiary of Merck...CompletedEssential ThrombocythemiaUnited States, Australia, New Zealand, United Kingdom, Hong Kong, Germany, Italy
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Imago BioSciences, Inc., a subsidiary of Merck...Active, not recruitingPrimary Myelofibrosis | Thrombocythemia, EssentialUnited States, Australia, Hong Kong, Germany, Italy, New Zealand, United Kingdom
-
University of WashingtonNational Cancer Institute (NCI); Imago BioSciences, Inc., a subsidiary of Merck...SuspendedExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell CarcinomaUnited States
-
Imago BioSciences, Inc., a subsidiary of Merck...CompletedAcute Myeloid Leukemia | Myelodysplastic SyndromeAustralia